Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Kalunian

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.
Mobile DNA|November 4, 2025
High interferon response signatures in SLE patient leukocytes are associated with increased transposable element expression in gene introns and intergenic regionsLeo J Arteaga-Vazquez, Hugo Sepulveda, Bruno Villalobos Reveles, et al.
The Journal of Rheumatology|January 12, 2007
The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritisSarah E Cassell, Jeffry D Bieber, Phoebe Rich, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Annals of the Rheumatic Diseases|June 4, 2015
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, et al.
The Lancet. Rheumatology|July 23, 2025
Reassessing antimalarial use in long-term SLE clinical trials - Authors' replyVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
ACR Open Rheumatology|June 15, 2026
Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus ErythematosusEdward M Vital, Zahir Amoura, Kenneth C Kalunian, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 9, 2018
Prevalence of Crystals in Knee Osteoarthritis: Experience From Patients Undergoing Arthroscopic ProceduresRobert Ike, Amrutha Baskaran, Jeannie Chao, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
The Lancet. Rheumatology|January 30, 2024
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabVibeke Strand, Sean O'Quinn, Richard A Furie, et al.
Mobile DNA|November 4, 2025
High interferon response signatures in SLE patient leukocytes are associated with increased transposable element expression in gene introns and intergenic regionsLeo J Arteaga-Vazquez, Hugo Sepulveda, Bruno Villalobos Reveles, et al.
The Journal of Rheumatology|January 12, 2007
The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritisSarah E Cassell, Jeffry D Bieber, Phoebe Rich, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
Annals of the Rheumatic Diseases|June 4, 2015
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, et al.
The Lancet. Rheumatology|July 23, 2025
Reassessing antimalarial use in long-term SLE clinical trials - Authors' replyVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
ACR Open Rheumatology|June 15, 2026
Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus ErythematosusEdward M Vital, Zahir Amoura, Kenneth C Kalunian, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 9, 2018
Prevalence of Crystals in Knee Osteoarthritis: Experience From Patients Undergoing Arthroscopic ProceduresRobert Ike, Amrutha Baskaran, Jeannie Chao, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Pageof 9